Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Intervention not reported

Serious adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma

The review found no eligible studies for this question.

1 finding from 1 review

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes only
Risk Ratio 1.18 [1.02, 1.37]
3 studies · 1644 participants
Moderate